mary mccormack & jonathan ledermann ncri gynae clinical studies group
TRANSCRIPT
![Page 1: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/1.jpg)
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group
![Page 2: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/2.jpg)
CRT standard of care for the past decade
Meta- analysis 18 RCT in CRT (Vale et al 2008)
-absolute survival benefit of 6% at 5 years
- all groups benefitted 7-10% stage I-II 3% stage III-IV
![Page 3: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/3.jpg)
Overall survival with CRT 66% at 5years (Vale 2008) – but DFS only 58%
However – in those with : positive LN large volume tumours advanced stage outcome remains poor
![Page 4: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/4.jpg)
Downstage
Eradicate micrometastases
Impact on survival ? Chemotherapy : short cycle interval 7% improvement in 5 year OS (Tierney 2003)
![Page 5: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/5.jpg)
Phase II single arm NCRI feasability study
Aim to assess response rate and toxicity of a short course of dose dense weekly chemotherapy prior to definitive chemoradiation in women with LACC
![Page 6: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/6.jpg)
Dose dense schedules- enhanced cell kill ? overcome accelerated repopulation ?
Greater dose intensity (v q 3-weekly) Well tolerated in head & neck / ovarian cancer
patients
![Page 7: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/7.jpg)
Histologically confirmed FIGO stage Ib2- IVa (Squamous, Adenocarcinoma, Adenosquamous)
PS 0,1
Age >18,no upper limit providing deemed fit to receive CRT Adequate renal,liver,BM function,normal ECG
Informed consent
![Page 8: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/8.jpg)
Weekly Paclitaxel (80mg/m2) & Weeks 1-6 Carboplatin (AUC2)
Followed by radical ChemoRT Weeks 7-13 (cisplatin 40 mg/m2)
![Page 9: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/9.jpg)
50 patients with LACC- (80% power , one sided test at 5% level to detect a response rate of at least 85%)
Toxicity rate >20% - trial to be stopped
![Page 10: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/10.jpg)
46 patients recruited from 3 centres
Median age 43 (range 23-71)
Histology -72% SCC -22% Adeno - 6% Adenosq
![Page 11: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/11.jpg)
FIGO stage IB2 - 11% II - 50% ( 3/23 +PALN) III - 33% (3/15 +PALN) Iva - 6%
![Page 12: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/12.jpg)
NACT CRT
G3/4 Haematological 11%
G3/4 Non-haem tox – 11%
G3/4 Haematological 45%
G3/4 Non- haem tox 21%
![Page 13: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/13.jpg)
![Page 14: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/14.jpg)
96% (44/46 ) completed RT without delay
96% (42/44) completed brachytherapy
78% (36/46) had minimum 4 cycles weekly cisplatin
![Page 15: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/15.jpg)
44 pts assessable for response
CR/PR - Post NACT - 68% [95% CI 52-81%] -12 Weeks post CRT - 82% [95% CI 67-92%]
Positive PALN 6 pts- 5 completed all treatment
4/5 NED
![Page 16: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/16.jpg)
Dose dense NACT with weekly C&P followed by radical CRT is feasible with acceptable toxicity
High response rate (68%) to short course of induction chemotherapy
NACT did not result in any disruption to CRT
![Page 17: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/17.jpg)
89% completed CRT within 50 days and 78% completed at least 4 cycles of cisplatin
Survival at 2 years is 79% (median FU 23.2 months)
This approach merits further investigation in a randomised phase 3 trial
![Page 18: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/18.jpg)
![Page 19: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/19.jpg)
Include all those suitable & fit for CRT
Stratify according to node status
Stratify according to RT dose / institution
Record tumour vol in addition to FIGO stage
![Page 20: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/20.jpg)
Collection of tissue for translational research
Substudy of functional imaging to assess response to IC - ?DCE- MRI
QOL assessment
![Page 21: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/21.jpg)
Primary endpoint - OS at 5 years
Secondary endpoints- PFS Toxicity QOL Pattern relapse Relationship between functional
imaging and outcome
![Page 22: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/22.jpg)
Sample size of 1100 provide 80% power to detect a 7% increase in 5 year OS ( 66 to 73%) (HR 0.75 , 2 sided test at 5% level)
Assumes accrual over 4 years with 4 years FU
![Page 23: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/23.jpg)
![Page 24: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/24.jpg)
Upfront chemotherapy
Short course 6 weeks
Minimal toxicity
No disruption to CRT
Overall treatment time 13 weeks
Outback chemotherapy
4 cycles q3weeks
Haem/GI tox likely to be significant
Compliance likely to be poor
Overall treatment time 20 weeks
![Page 25: Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group](https://reader035.vdocuments.us/reader035/viewer/2022062314/56649dac5503460f94a9b0e4/html5/thumbnails/25.jpg)
differences in expertise –radiology/ nodal staging
variations in RT dose & fractitionation
quality assurance for RT etc
Potential difficulties in delivering a protracted course of treatment & in FU
These need to be addressed as the participation of colleagues in developing world & Eastern Europe is essential